Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial.

ABSTRACT: Aims:We created a new index (Multi Inflammatory Index, MII) composed of an inflammatory index [neutrophil-to lymphocyte-ratio (NLR): MII-1; platelet-to-lymphocyte ratio (PLR): MII-2; or systemic immune-inflammation index (SII): MII-3] and C-reactive protein (CRP). Our aim was to evaluate the prognostic and/or predictive capacity of the MII in the randomized ITACa (Italian Trial in Advanced Colorectal Cancer) study on patients with metastatic colorectal cancer undergoing first-line chemotherapy. Methods:Between November 2007 and March 2012, baseline NLR, PLR; SII and CRP were available for 131 patients, 66 receiving chemotherapy plus bevacizumab and 65 receiving chemotherapy alone. Results:Patients with low (<25) MII-1 levels had a better outcome than those with high (?25) levels: median progression-free survival (PFS) was 12.4 versus 8.9?months [hazard ratio (HR)?=?1.74, 95% confidence interval (CI) 1.21-2.51, p?=?0.003] and median overall survival (OS) was 30.9?months versus 15.0?months (HR?=?2.05, 95% CI 1.40-3.02, p?=?0.0002), respectively. Similar results were obtained for patients with low (<1424) MII-2 levels compared with those with high (?1424) levels: median PFS was 12.6 versus 8.9?months (HR?=?1.95, 95% CI 1.35-2.82, p?=?0.0004) and median OS was 32.4 versus 14.6?months, respectively (HR?=?2.42, 95% CI 1.64-3.57, p?

SUBMITTER: Casadei Gardini A 

PROVIDER: S-EPMC7534088 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature